Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma-Where we are and where we're headed.
Blood-based tests now predict treatment outcomes in lymphoma better than imaging, helping doctors tailor therapy intensity to individual risk.
This review covers how ctDNA-based MRD assessment is transforming NHL treatment decisions, with ctDNA outperforming PET for outcome prediction in DLBCL. Prospective trials are testing MRD-guided therapy de-escalation across NHL subtypes.
What the study was
- Study design
- Review
- Population
- Patients with non-Hodgkin lymphoma
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Seminars in Hematology
Why it surfaced
Comprehensive review from NCI on MRD-guided treatment in NHL — highly relevant to hematologic malignancies and liquid biopsy watchlist. Review type limits design score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.